$182 Million is the total value of Prosight Management, LP's 43 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 67.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PRTA | Sell | PROTHENA CORP PLC | $23,029,000 | +6.1% | 323,300 | -23.4% | 12.67% | -6.6% |
| ALBO | Buy | ALBIREO PHARMA INC | $13,885,000 | +33.8% | 445,020 | +50.8% | 7.64% | +17.7% |
| GLPG | Buy | GALAPAGOS NVspon adr | $13,188,000 | +165.9% | 250,680 | +248.2% | 7.26% | +134.0% |
| CUE | Buy | CUE BIOPHARMA INC | $9,546,000 | +30.0% | 655,185 | +3.9% | 5.25% | +14.4% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $9,135,000 | -2.2% | 153,400 | +12.0% | 5.03% | -14.0% |
| ZGNX | Buy | ZOGENIX INC | $7,456,000 | +41.1% | 490,882 | +60.5% | 4.10% | +24.2% |
| IOVA | Buy | IOVANCE BIOTHERAPEUTICS INC | $6,776,000 | +87.5% | 274,761 | +97.8% | 3.73% | +65.0% |
| ALDX | Buy | ALDEYRA THERAPEUTICS INC | $6,453,000 | -4.3% | 735,000 | +23.5% | 3.55% | -15.8% |
| CNVY | Buy | CONVEY HLDG PARENT INC | $6,199,000 | +32.7% | 738,012 | +79.8% | 3.41% | +16.8% |
| XCUR | Buy | EXICURE INC | $6,150,000 | +13.9% | 5,125,000 | +42.4% | 3.38% | +0.2% |
| KZR | Sell | KEZAR LIFE SCIENCES INC | $5,443,000 | -2.1% | 629,957 | -38.5% | 3.00% | -13.8% |
| New | GALAPAGOS NVcall | $5,261,000 | – | 100,000 | +100.0% | 2.90% | – | |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $4,491,000 | +3.5% | 257,391 | +42.1% | 2.47% | -9.0% |
| ACCD | New | ACCOLADE INC | $4,132,000 | – | 97,988 | +100.0% | 2.27% | – |
| MORF | Buy | MORPHIC HLDG INC | $3,965,000 | +7.5% | 70,000 | +8.9% | 2.18% | -5.4% |
| MTCR | Buy | METACRINE INC | $3,927,000 | +18.9% | 1,145,034 | +31.8% | 2.16% | +4.6% |
| MGTX | Buy | MEIRAGTX HLDGS PLC | $3,836,000 | -9.5% | 291,080 | +6.4% | 2.11% | -20.4% |
| HUM | New | HUMANA INC | $3,502,000 | – | 9,000 | +100.0% | 1.93% | – |
| STTK | New | SHATTUCK LABS INC | $3,449,000 | – | 169,241 | +100.0% | 1.90% | – |
| OSCR | Buy | OSCAR HEALTH INCcl a | $3,276,000 | +177.2% | 188,400 | +242.5% | 1.80% | +143.8% |
| New | PROGYNY INCput | $3,080,000 | – | 55,000 | +100.0% | 1.70% | – | |
| AMED | New | AMEDISYS INC | $2,982,000 | – | 20,000 | +100.0% | 1.64% | – |
| AGL | New | AGILON HEALTH INC | $2,870,000 | – | 109,510 | +100.0% | 1.58% | – |
| VRTX | Sell | VERTEX PHARMACEUTICALS INC | $2,721,000 | -50.2% | 15,000 | -44.6% | 1.50% | -56.2% |
| HAE | Sell | HAEMONETICS CORP MASS | $2,705,000 | -69.7% | 38,319 | -71.4% | 1.49% | -73.4% |
| ABBV | New | ABBVIE INC | $2,675,000 | – | 24,800 | +100.0% | 1.47% | – |
| New | IOVANCE BIOTHERAPEUTICS INCcall | $2,466,000 | – | 100,000 | +100.0% | 1.36% | – | |
| EHC | Sell | ENCOMPASS HEALTH CORP | $2,375,000 | -65.4% | 31,647 | -64.0% | 1.31% | -69.6% |
| PRQR | Sell | PROQR THRAPEUTICS N V | $2,362,000 | -16.6% | 282,256 | -32.8% | 1.30% | -26.6% |
| IRTC | Buy | IRHYTHM TECHNOLOGIES INC | $2,190,000 | +63.4% | 37,396 | +85.1% | 1.20% | +43.8% |
| ZBH | Sell | ZIMMER BIOMET HOLDINGS INC | $1,903,000 | -62.4% | 13,000 | -58.7% | 1.05% | -67.0% |
| PANA | New | PANACEA ACQUISITION CORP II | $1,846,000 | – | 188,940 | +100.0% | 1.02% | – |
| WAT | New | WATERS CORP | $1,429,000 | – | 4,000 | +100.0% | 0.79% | – |
| UNH | Sell | UNITEDHEALTH GROUP INC | $1,289,000 | -35.6% | 3,300 | -34.0% | 0.71% | -43.4% |
| CLLS | Buy | CELLECTIS S Aspon ads | $1,098,000 | -17.5% | 87,103 | +1.2% | 0.60% | -27.4% |
| SIOX | Buy | SIO GENE THERAPIES INC | $1,070,000 | +53.1% | 493,208 | +92.6% | 0.59% | +34.8% |
| ASMB | Buy | ASSEMBLY BIOSCIENCES INC | $924,000 | +59.9% | 265,634 | +78.2% | 0.51% | +40.7% |
| ALEC | New | ALECTOR INC | $625,000 | – | 27,378 | +100.0% | 0.34% | – |
| LFST | New | LIFESTANCE HEALTH GROUP INC | $562,000 | – | 38,774 | +100.0% | 0.31% | – |
| ORGO | Buy | ORGANOGENESIS HLDGS INC | $541,000 | +29.7% | 38,000 | +51.4% | 0.30% | +14.2% |
| ONCR | Buy | ONCORUS INC | $518,000 | -24.9% | 55,411 | +10.8% | 0.28% | -33.9% |
| MDXG | New | MIMEDX GROUP INC | $268,000 | – | 44,225 | +100.0% | 0.15% | – |
| Sell | APTOSE BIOSCIENCES INC | $154,000 | -65.2% | 70,563 | -46.9% | 0.08% | -69.2% | |
| ADMA | Exit | ADMA BIOLOGICS INC | $0 | – | -115,100 | -100.0% | -0.12% | – |
| CANO | Exit | CANO HEALTH INC | $0 | – | -23,200 | -100.0% | -0.18% | – |
| RPHM | Exit | RENEO PHARMACEUTICALS INC | $0 | – | -54,934 | -100.0% | -0.32% | – |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -87,813 | -100.0% | -0.36% | – |
| OPCH | Exit | OPTION CARE HEALTH INC | $0 | – | -27,875 | -100.0% | -0.38% | – |
| NUVB | Exit | NUVATION BIO INC | $0 | – | -91,694 | -100.0% | -0.53% | – |
| Exit | AURINIA PHARMACEUTICALS INCcall | $0 | – | -67,200 | -100.0% | -0.54% | – | |
| Exit | AKUMIN INC | $0 | – | -327,680 | -100.0% | -0.64% | – | |
| CLOV | Exit | CLOVER HEALTH INVESTMENTS CO | $0 | – | -79,100 | -100.0% | -0.66% | – |
| EVH | Exit | EVOLENT HEALTH INCcl a | $0 | – | -52,023 | -100.0% | -0.69% | – |
| Exit | ALBIREO PHARMA INCcall | $0 | – | -32,900 | -100.0% | -0.72% | – | |
| MDT | Exit | MEDTRONIC PLC | $0 | – | -11,000 | -100.0% | -0.85% | – |
| ATIP | Exit | ATI PHYSICAL THERAPY INC | $0 | – | -173,276 | -100.0% | -1.03% | – |
| AUPH | Exit | AURINIA PHARMACEUTICALS INC | $0 | – | -130,000 | -100.0% | -1.05% | – |
| LHCG | Exit | LHC GROUP INC | $0 | – | -9,888 | -100.0% | -1.24% | – |
| QSI | Exit | QUANTUM SI INC | $0 | – | -227,391 | -100.0% | -1.74% | – |
| RCM | Exit | R1 RCM INC | $0 | – | -171,817 | -100.0% | -2.39% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALDEYRA THERAPEUTICS INC | 19 | Q2 2023 | 6.2% |
| ALBIREO PHARMA INC | 18 | Q4 2022 | 9.2% |
| MEIRAGTX HOLDINGS PLC | 18 | Q3 2023 | 6.3% |
| KEZAR LIFE SCIENCES INC | 17 | Q3 2023 | 8.2% |
| ARENA PHARMACEUTICALS INC | 16 | Q4 2021 | 8.2% |
| IOVANCE BIOTHERAPEUTICS INC | 16 | Q1 2022 | 7.7% |
| CENTENE CORP DEL | 16 | Q3 2023 | 5.3% |
| CUE BIOPHARMA INC | 14 | Q1 2023 | 5.6% |
| PROTHENA CORP PLC | 13 | Q3 2023 | 13.6% |
| ZIMMER BIOMET HOLDINGS INC | 13 | Q3 2021 | 9.8% |
View Prosight Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| EXICURE, INC. | February 14, 2022 | 2,426,508 | 2.2% |
| Aldeyra Therapeutics, Inc. | February 12, 2021 | 908,488 | 2.3% |
| Teligent, Inc. | February 14, 2020 | 1,484,527 | 2.8% |
| Cidara Therapeutics, Inc. | February 14, 2019 | 245,764 | 0.9% |
| Eiger BioPharmaceuticals, Inc.Sold out | February 14, 2019 | 0 | 0.0% |
| Millendo Therapeutics, Inc. | February 14, 2019 | 256,739 | 2.0% |
| OvaScience, Inc. | October 26, 2018 | 1,991,100 | 5.6% |
| CHIMERIX INC | February 13, 2018 | 1,478,519 | 3.1% |
| Harvard Apparatus Regenerative Technology, Inc. | February 12, 2016 | 184,360 | 1.4% |
View Prosight Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G | 2024-01-02 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-09-01 |
View Prosight Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.